CCL Pharma


Concise Prescribing Info
Resp infections including acute sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated & complicated skin & skin structure infections, complicated intra-abdominal infections including polymicrobial infections eg, abscess. As 2nd-line agent in TB.
Dosage/Direction for Use
Recommended dose: 400 mg once daily. Duration of treatment: 3-4 days. Acute bacterial sinusitis, uncomplicated skin & skin structure infections 400 mg daily for 7 days. Acute bacterial exacerbation of chronic bronchitis 400 mg daily for 5 days. Community-acquired pneumonia 400 mg daily for 10 days. Complicated skin & skin structure infections 400 mg daily for 7-21 days. Complicated intra-abdominal infections 400 mg daily for 5-14 days.
May be taken with or without food: Swallow whole. Avoid antacids or supplements containing Fe or Zn 4 hr before or 8 hr after moxifloxacin. Ensure adequate hydration.
Hypersensitivity to moxifloxacin or other quinolones. History of tendon disorder related to quinolone treatment. Documented QT prolongation.
Special Precautions
Avoid in patients w/ known prolongation of QT interval, hypokalemia, receiving Class IA or Class III antiarrhythmic agents. May cause CNS stimulation & psychiatric effects. Discontinue if signs of hypersensitivity appears (eg, skin rash), pain, inflammation or rupture of a tendon. Avoid excessive sunlight or artificial UV light. Pseudomembranous colitis. Moderate or severe hepatic impairment. Advanced renal impairment. Pregnancy & lactation. Childn ≤18 yr.
Adverse Reactions
Palpitation, QT prolongation, tachycardia, vasodilation; anxiety, chills, dizziness, headache, insomnia, malaise, nervousness, pain, somnolence, tremor, vertigo; dry skin, pruritus, rash (maculopapular, purpuric, pustular); endocrine & metabolic effects; abdominal pain, increased/decreased amylase, anorexia, constipation, dry mouth, dyspepsia, flatulence, glossitis, increased lactic dehydrogenase, stomatitis, taste perversion, vomiting; vag moniliasis, vaginitis; hematologic effects eg, eosinophilia, leukopenia, prolonged prothrombin time, increased INR, thrombocythemia; decreased or increased bilirubin, increased gamma-glutamyl transpeptidase, abnormal liver function test; arthralgia, myalgia, weakness; increased serum albumin; pharyngitis, pneumonia, rhinitis, sinusitis, increased pO2; allergic reaction, infection, diaphoresis, oral moniliasis.
Drug Interactions
Absorption may be interfered by antacids containing Al or Mg; sucralfate, metal cations or multivit containing Fe or Zn. Enhanced anticoagulant effects of warfarin. Increased risk of CNS stimulation & convulsions w/ concomitant administration of NSAIDs.
MIMS Class
ATC Classification
J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
Molox FC tab 400 mg
Molox infusion 400 mg
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in